P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US
Adam F. Binder,
Urvi A. Shah,
Niodita Gupta-Werner,
Hui Lu,
Malavika Venkatraman,
Jennifer Whitty,
Vipin Khare,
Olivia Costa,
Shuchita Kaila,
Brea C. Lipe
Affiliations
Adam F. Binder
1 Sidney Kimmel Cancer Center, Thomas Jefferson University, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Philadelphia, United States
Urvi A. Shah
2 Memorial Sloan Kettering Cancer Center, New York, United States
Niodita Gupta-Werner
4 Janssen Scientific Affairs, LLC., Horsham, United States
Hui Lu
5 Evidera, London, United Kingdom
Malavika Venkatraman
5 Evidera, London, United Kingdom
Jennifer Whitty
5 Evidera, London, United Kingdom
Vipin Khare
4 Janssen Scientific Affairs, LLC., Horsham, United States
Olivia Costa
4 Janssen Scientific Affairs, LLC., Horsham, United States
Shuchita Kaila
4 Janssen Scientific Affairs, LLC., Horsham, United States
Brea C. Lipe
6 University of Rochester Medical Center, Rochester, United States
